my personal edition > asthma > news
E-Mail this DGReview to a colleague
DGReview
Investigational Model Tests Anti-Exudative Effect Of New Asthma Drugs
A DGReview of :"Assessment of Microvascular Leakage via Sputum Induction: The Role of Substance P and Neurokinin A in Patients with Asthma"
American Journal of Respiratory and Critical Care Medicine
05/16/2002
By Elda Hauschildt
An investigational model of dual induction microvascular leakage could be useful in testing the anti-exudative effect of newly developed drugs in asthma patients.
Dutch researchers from Leiden University Medical Centre describe dual induction as first leakage and then sputum.
Testing the model using a potent neurokinin 1 (NK1) agonist in 12 patients with atopic, mild steroid-naïve asthma, the investigators say that microvascular leakage is an important feature in inflammation, but its assessment has seldom been used to monitor airway inflammation in asthma.
The researchers evaluated the effects of inhaled substance P, an NK1 agonist and mediator of plasma extravasation, on markers of microvascular leakage in the sputum of the asthma patients.
Sputum was in participants before, and 30 minutes after, inhalation of substance P or neurokinin A, the control substance. Markers of leakage in induced sputum included a2-macroglobulin, ceruloplasmin, albumin and fibrinogen.
Substance P induced a significant increase in levels of a2-macroglobulin, ceruloplasmin and albumin. Inhaled neurokinin A did not induce significant changes. "Increase in sputum leakage markers was not associated with the cumulative dose of substance P."
American Journal of Respiratory and Critical Care Medicine, 2002; 165: 1275-1279
"Assessment of Microvascular Leakage via Sputum Induction: The Role of Substance P and Neurokinin A in Patients with Asthma"
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
